The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT03667014
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a single-arm, open-label study, which will examine the effect of dupilumab on quality of life in atopic dermatitis patients.

Key Dates

Start date
Nov 1, 2018
Status verified
Dec 2023
Primary completion
Dec 15, 2022
Completion
Dec 15, 2022

Study Design

Enrollment
34 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dupilumab treatment
    30 subjects will receive dupilumab for a treatment period of 52 weeks. All patients quality of life measures will be assessed with Psychological General Well-Being scale (PGWB), Work Productivity and Activity Impairment scale (WPAI), and Dermatology Life Quality Index (DLQI). Symptom and satisfaction will be assessed with Treatment Satisfaction Questionnaire for Medication (TSQM), Itch Numerical Rating Scale, Pain Numerical Rating Scale, and Pittsburgh Sleep Quality Assessment (PSQI).

Primary Outcome Measure

Psychological General Well-Being Scale (PGWB) [ Time Frame: 16 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
UCSF Psoriasis and Skin Treatment CenterSan FranciscoCalifornia94118-

Find similar trials in San Francisco, CA

By condition
Atopic dermatitis / eczema
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
UCSF Psoriasis and Skin Treatment Center· San Francisco, CA

Related Studies